RxDoctor Payments DataLook up a doctor →

Shannon McAllister, MD

Dermatology · Louisville, KYNPI 1518971142

Payments from drug & device makers

$10,524in general payments, 2019–2025

Across 628 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novartis$1K
  • Johnson & Johnson$1K
  • Lilly USA, LLC$865
  • Regeneron Healthcare Solutions, Inc.$755
  • Sanofi$472
  • plus $4K from 27 others

What the payments were for

  • Food & beverage$10,24397%
  • Education$2813%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,524 in reported general payments places this provider in the 75th percentile of 128 dermatology providers in Kentucky.

See all dermatology providers in Kentucky

Medicare billing

Part B allowed, 2024
$304,046
Medicare patients
1,226
Services billed
5,149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Unoready PenSecukinumab11$123,939
Dupixent PenDupilumab24$92,855
OtezlaApremilast13$62,873
Dupixent SyringeDupilumab13$48,453
OpzeluraRuxolitinib Phosphate16$31,798
Clobetasol Propionate130$3,540
Betamethasone Dipropionate88$3,270
Fluorouracil40$2,886
Ketoconazole130$1,907
Triamcinolone Acetonide149$1,427
Fluocinonide24$1,369
ValacyclovirValacyclovir Hcl37$1,315
Tretinoin21$1,221
Metronidazole12$951
Clindamycin Phosphate33$923

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$444$62,87313 claims
Incyte CorporationOpzelura$286$31,79816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 128 dermatology providers in Kentucky.

Other dermatology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →